BAY 2927088, an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant HER2, led to promising response rates when used for the treatment of patients with pretreated HER2 ...
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1]. The trial investigated ...